K
KNSA
Kiniksa Pharmaceuticals Internat…
47.22
-1.72-3.51%Opening11:03 04/08 EDT
OPEN/PREV CLOSE49.23/48.94
TODAY RANGE46.75-49.64
VOL151.29K
MARKET CAP3.61B
52 WEEK RANGE18.26-50.03
AVG VOL (3M)645.03K
% TURNOVER0.20%
TURNOVER--
P/E (TTM)63.20
% RANGE5.91%
EPS(TTM)0.7471
P/E(FORWARD)41.28
P/B6.35
BVPS7.44
DIVIDEND--
P/S5.32
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.09B
SHARES OUTSTANDING76.54M
NEXT EARNINGS04/21-05/02
FREE FLOAT44.22M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·2h ago
Kiniksa launches direct-to-consumer campaign for Arcalyst
Simply Wall St·3d ago
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation As Earnings Growth Supports Profitability And Shares Trade Near 52 Week High
TipRanks·03/11 00:23
Kiniksa Pharmaceuticals Earnings Call Highlights ARCALYST Surge
Simply Wall St·03/06 21:24
A Look At Kiniksa Pharmaceuticals International’s Valuation After Strong 2025 Growth And ARCALYST Commercial Momentum
Reuters·03/04 21:41
Kiniksa Pharmaceuticals CMO John F. Paolini Disposes of Common Shares
Simply Wall St·03/04 16:29
How Investors Are Reacting To Kiniksa (KNSA) Turning ARCALYST Revenue Into Full-Year Profitability And Flexibility
Simply Wall St·02/27 05:29
Is Kiniksa Pharmaceuticals (KNSA) Still Attractive After A 114% One-Year Share Price Surge?
Simply Wall St·02/26 03:42
Kiniksa Pharmaceuticals International (KNSA) Profitability Shift Tests Bullish High Growth Narratives
Benzinga·02/25 18:00
The Analyst Verdict: Kiniksa Pharmaceuticals In The Eyes Of 4 Experts
Dow Jones·02/25 15:04
Kiniksa Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Same Industry
Name/Symbol
Change%
Price